Home Heart Failure Symptoms Edwards invests in 2 companies to boost transcatheter heart treatment portfolio - Cardiovascular Business

Edwards invests in 2 companies to boost transcatheter heart treatment portfolio - Cardiovascular Business

2 min read

Edwards Lifesciences has invested $35 million for an exclusive right to acquire Corvia Medical, which is engaged in a U.S. pivotal trial for its InterAtrial Shunt Device (IASD) to treat heart failure.

The IASD provides continuous decompression of the left atrium, which may reduce symptoms and slow the progression of heart failure, according to Edwards. It is also the first transcatheter device designed to treat heart failure with preserved or midrange ejection fraction, the companies stated.

The device received CE mark approval in 2016, and the investment from Edwards will help Corvia complete the REDUCE LAP-HF II pivotal trial for seeking regulatory approval through the FDA.

"We are extremely pleased to have the support of the global leader in patient-focused innovations for structural heart disease as we continue to advance this novel treatment for heart failure," George Fazio, president and CEO of Corvia Medical, said in a press release. "We are proud of our accomplishments to date and look forward to completing the pivotal study with the support of our global clinical investigators."

Source link

Check Also

Gene-edited food quietly arrives in restaurant cooking oil - WRAL.com

By CANDICE CHOI, AP Food & Health Writer NEW YORK — Somewhere in the Midwest, a restau…